US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

289.72

-6.0450-2.04%

Volume:192.30K

Turnover:54.96M

Market Cap:557.55M

PE:- -

High:291.89

Open:288.00

Low:281.72

Close:295.76

52wk High:341.93

52wk Low:71.88

Shares:1.92M

Float Shares:1.92M

Volume Ratio:0.84

T/O Rate:9.99%

Dividend:1.01

Dividend Rate:0.35%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Alvotech Stock Gains After FDA Accepts for Review Crohn's Treatment AVT80

Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says

MT Newswires Live

Sunshine Lake Pharma Details Terms of New Healthcare-Focused Investment Fund

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)

Sector Update: Healthcare

MT Newswires Live

Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline

Karyopharm Seeks Accelerated FDA Approval for XPOVIO Combo

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)

Karyopharm submits sNDA to FDA for XPOVIO

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY)

Humana Stock And 2 Healthcare Names Backing The Shift To Preventive Care

Simply Wall St.

Takeda Pharmaceutical Says US FDA Approves Rusfertide for Rare Type of Blood Cancer

MT Newswires Live

Advicenne Pulls U.S. Application for Rare Kidney Drug ADV7103 After FDA Feedback

PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10%

MT Newswires Live

Promisia clears conditions for Chatswood Retirement Village acquisition

Regis Healthcare Director Boosts Stake with On-Market Share Purchase

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)

Fisher & Paykel Healthcare Issues New Shares for Employee Incentive Plans

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/LABU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":289.715,"timestamp":1788197078836,"preClose":295.76,"halted":0,"volume":192295,"delay":0,"changeRate":-0.020438869353529943,"floatShares":1924486,"shares":1924486,"eps":0,"marketStatus":"Trading","change":-6.045,"latestTime":"08-31 13:24:53 EDT","open":288,"high":291.89,"low":281.7229,"amount":54963401.022250004,"amplitude":0.034376,"askPrice":289,"askSize":350,"bidPrice":288.14,"bidSize":300,"shortable":0,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788206400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":295.76,"sharesOutstanding":3074486,"nav":295.545,"aum":568772231.45,"dividendRate":0.003471,"bidAskSpread":0.002847,"preHourTrading":{"tag":"盘前","latestPrice":288.18,"preClose":295.76,"latestTime":"09:29 EDT","volume":1523,"amount":449603.04808999994,"timestamp":1788182999999,"change":-7.58,"changeRate":-0.025629,"amplitude":0.050003},"postHourTrading":{"tag":"盘后","latestPrice":295.76,"preClose":295.76,"latestTime":"19:55 EDT","volume":2719,"amount":805526.7898,"timestamp":1787961358839,"change":0,"changeRate":0,"amplitude":0.003466},"volumeRatio":0.841208,"impliedVol":0.9313,"impliedVolPercentile":0.5817},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1924486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.841208,"shares":1924486,"dividePrice":1.0056,"high":291.89,"amplitude":0.034376,"preClose":295.76,"low":281.7229,"week52Low":71.88,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":289.715,"committee":-0.076923,"eps":0,"divideRate":0.003471,"volume":192295,"delay":0,"ttmEps":0,"open":288,"prevYearClose":159.39,"prevWeekClose":295.76,"prevMonthClose":227.4,"prevQuarterClose":292.1,"fiveDayClose":308.33,"twentyDayClose":228.04,"sixtyDayClose":179.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664867007","title":"Alvotech Stock Gains After FDA Accepts for Review Crohn's Treatment AVT80","url":"https://stock-news.laohu8.com/highlight/detail?id=2664867007","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664867007?lang=en_us&edition=fundamental","pubTime":"2026-09-01 00:56","pubTimestamp":1788195360,"startTime":"0","endTime":"0","summary":"Shares of Alvotech rose after the Food and Drug Administration accepted for review a biologics license application for a potential biosimilar for an ulcerative colitis and Crohn's disease treatment.Th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALVO","BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663215001","title":"Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2663215001","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663215001?lang=en_us&edition=fundamental","pubTime":"2026-08-31 22:48","pubTimestamp":1788187693,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals (ARWR) thinks Plozasiran could receive US Food and Drug Administration approval to treat severe hypertriglyceridemia, or sHTG, by the second quarter of 2027, RBC Capital Mark","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4139","SNY","BK4588","BK4007","LABU","ARWR","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663800191","title":"Sunshine Lake Pharma Details Terms of New Healthcare-Focused Investment Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2663800191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663800191?lang=en_us&edition=fundamental","pubTime":"2026-08-31 22:37","pubTimestamp":1788187062,"startTime":"0","endTime":"0","summary":"The latest update is out from Sunshine Lake Pharma Co., Ltd. Class H ( ($HK:6887) ). Sunshine Lake Pharma has detailed the terms of a newly establi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sunshine-lake-pharma-details-terms-of-new-healthcare-focused-investment-fund?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sunshine-lake-pharma-details-terms-of-new-healthcare-focused-investment-fund?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4588","HCSG","XLV","LABU","BK4585","LU0029874061.USD","LU0128526141.USD","BK4137","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663700958","title":"Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663700958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663700958?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:50","pubTimestamp":1788184220,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vor Biopharma (VOR), Definium Therapeutics (DFTX) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-definium-therapeutics-dftx-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-definium-therapeutics-dftx-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","LU0029874061.USD","LU0128526141.USD","BK4588","IDYA","XBI","BK4137","BK4581","LABU","XLV","BK4585","BK4139","DFTX","BK4007","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663200514","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2663200514","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663200514?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:04","pubTimestamp":1788181452,"startTime":"0","endTime":"0","summary":"Healthcare stocks were falling premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) down 0.6%.Arrowhead Pharmaceuticals' ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","HCSG","IBB","BK4137","BK4585","XLV","XBI","ARWR","LU0128526141.USD","BK4581","LU0029874061.USD","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663009418","title":"Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2663009418","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663009418?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:30","pubTimestamp":1788179400,"startTime":"0","endTime":"0","summary":"Company views federal support for Schedule III as a significant evolution in U.S. cannabinoid policy and an important step toward a durable regulatory framework for cannabinoid-based medicines and wel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353300/0/en/endovia-health-sciences-welcomes-historic-shift-in-federal-cannabinoid-policy-advances-cannepil-fda-submission-and-expands-development-pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0612318385.USD","LU0496367417.USD","LU0330918003.SGD","BK4161","LU0648000940.SGD","LU0788109121.HKD","LU0724618789.USD","SG9999002521.SGD","BK4585","BK4017","LU0612318971.USD","LU0130103400.USD","LU0345781412.USD","BK4588","BK4113","LU0075056555.USD","LU0498741890.SGD","LU0498741114.HKD","LU0055631609.USD","LU0368265764.SGD","CBD","BK4185","BU","LABU","LU0345780281.USD","SG9999001143.SGD","B","THC","LU1023059493.AUD","LU0345780521.USD","LU0654597011.USD","LU1201861165.SGD","LU0345780950.USD","LU0630314457.HKD","LU0300736492.USD","LU0300736062.USD","LU0963586101.USD","LU2324357040.USD","LU1430597077.USD","LU0788108826.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663431003","title":"Karyopharm Seeks Accelerated FDA Approval for XPOVIO Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663431003","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663431003?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:28","pubTimestamp":1788179295,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics ( ($KPTI) ) has shared an update. On August 31, 2026, Karyopharm Therapeutics Inc. said it has submitted a supplemental New...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/karyopharm-seeks-accelerated-fda-approval-for-xpovio-combo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/karyopharm-seeks-accelerated-fda-approval-for-xpovio-combo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663490008","title":"Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2663490008","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663490008?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"BERKELEY HEIGHTS, N.J., Aug.  31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353242/0/en/kalaris-to-present-at-morgan-stanley-24th-annual-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4137","LU0128526141.USD","XBI","BK4581","BK4588","HCSG","LU0029874061.USD","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008480","title":"Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008480","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008480?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353254/0/en/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-meeting-for-phase-3-registration-study-of-cad-1005-in-heparin-induced-thrombocytopenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LABU","LENZ","BK4134","BK4007","BK4613","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4539","HIT","BK4173","BK4023","KD","IE0031619046.USD","SAP","IE00B7SZL793.SGD","BK4139","BK4528"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008638","title":"Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008638?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:50","pubTimestamp":1788177029,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNT...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alnylam-pharma-alny-lakefront-biotherapeutics-lkft-and-biontech-se-bntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alnylam-pharma-alny-lakefront-biotherapeutics-lkft-and-biontech-se-bntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HCSG","LU0320765992.SGD","BNTX","BK4548","LKFT","LU0882574055.USD","PBE","LU0889565916.HKD","LU0029874061.USD","BK4568","BK4588","GNMX","XBI","BK4581","BK4137","BK4551","LU0128526141.USD","LU0114720955.EUR","BK4535","LABU","XLV","ALNY","BK4585","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663407048","title":"Karyopharm submits sNDA to FDA for XPOVIO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663407048","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663407048?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:36","pubTimestamp":1788176162,"startTime":"0","endTime":"0","summary":"Karyopharm (KPTI) Therapeutics announced that it has submitted a supplemental New Drug Application, sNDA, to the U.S. Food and Drug Administration,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/karyopharm-submits-snda-to-fda-for-xpovio-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/karyopharm-submits-snda-to-fda-for-xpovio-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","LABU","KPTI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079169","title":"Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663079169?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:30","pubTimestamp":1788168608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Alnylam Pharma (ALNY) wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-boston-scientific-bsx-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-boston-scientific-bsx-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1720051108.HKD","LU1989764748.USD","LU1720051017.SGD","LU2491050071.SGD","LU1153585028.USD","IE00BFTCPJ56.SGD","LU0353189763.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU1804176565.USD","LU0889565916.HKD","GNMX","LU0251132253.USD","LU2506951958.HKD","PBE","LU0114720955.EUR","LU2362541513.USD","XBI","BK4581","LU2506952170.USD","LU0048584097.USD","LU0109394709.USD","LU2362540622.SGD","LU0128526141.USD","LU2112291526.USD","BK4504","LU0138981039.USD","LU1989772840.SGD","BK4585","IE0009355771.USD","LU2242649171.HKD","BSX","BK4548","HCSG","LU0345769631.USD","LU1718418525.SGD","IE0002141913.USD","LABU","LU1057294990.SGD","LU2244417387.USD","LU0077335932.USD","LU0225283273.USD","LU1791710400.SGD","XLV","IE00BJJMRZ35.SGD","BK4139","ALNY","LU0266013472.USD","LU0267386448.USD","LU1989764664.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077852","title":"Humana Stock And 2 Healthcare Names Backing The Shift To Preventive Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077852","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077852?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:25","pubTimestamp":1788168318,"startTime":"0","endTime":"0","summary":"Investors are watching a cultural pivot as more people question hyper quantified wellness and look for care that treats the whole person instead of just the data points. That shift could reshape where money flows across healthcare and wellness. Miss it and you could overlook companies that fit this mood. This article breaks down three stocks from our Holistic and Preventive Healthcare & Wellness Providers screener that appear closely tied to this news story.\nThe stocks highlighted below are a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-stock-and-2-healthcare-names-backing-the-shift-to-pre","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-stock-and-2-healthcare-names-backing-the-shift-to-pre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HCSG","BK4154","LU1093756325.SGD","LU0390134368.USD","LU0128526141.USD","BK4581","SG9999014021.USD","BK4539","LU0029874061.USD","LU0070302665.USD","BK4137","BK4585","XLV","SG9999014013.SGD","BK4533","BK4566","LU0211331839.USD","BK7093","BK4588","LU0320765489.SGD","LU1093756168.USD","LU0170899867.USD","LU0266013472.USD","PRVA","LU0256863811.USD","LU0348723411.USD","LU0208291251.USD","BK7500","HUM.AU","FXH","LU0417517546.SGD","LABU","IHF","XBI","SG9999014005.SGD","HUM","LU0238689110.USD","BK6088","Z4D.SI","BK6046","BK4196","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663073421","title":"Takeda Pharmaceutical Says US FDA Approves Rusfertide for Rare Type of Blood Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2663073421","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663073421?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:24","pubTimestamp":1788164657,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical  said late Friday the US Food and Drug Administration approved rusfertide for the treatment of erythrocytosis in adults with polycythemia vera, a rare type of blood cancer.The approval is supported by data from a phase 3 study that showed rusfertide plus standard of care demonstrated higher response rate, including hematocrit control, reduced phlebotomy and improved fatigue compared with placebo plus standard of care, the company said.The treatment was generally well tolerated through 52 weeks, with injection-site reactions and anemia among the most common treatment-emergent adverse events, Takeda said.The approval does not change Takeda's consolidated financial guidance for fiscal 2026, it said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4007","TAK","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663022687","title":"Advicenne Pulls U.S. Application for Rare Kidney Drug ADV7103 After FDA Feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=2663022687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663022687?lang=en_us&edition=fundamental","pubTime":"2026-08-31 13:38","pubTimestamp":1788154682,"startTime":"0","endTime":"0","summary":"Advicenne SA ( ($FR:ALDVI) ) has shared an announcement. Advicenne has voluntarily withdrawn its New Drug Application to the U.S. Food and Drug Adm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/advicenne-pulls-u-s-application-for-rare-kidney-drug-adv7103-after-fda-feedback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/advicenne-pulls-u-s-application-for-rare-kidney-drug-adv7103-after-fda-feedback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663024641","title":"PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663024641","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663024641?lang=en_us&edition=fundamental","pubTime":"2026-08-31 12:50","pubTimestamp":1788151819,"startTime":"0","endTime":"0","summary":"PharmaEssentia  has received approval from the US Food and Drug Administration for BESREMi  solution for injection in a pre-filled syringe of 500 mcg/mL and in a pre-filled pen injector 500 mcg/0.5 mL, according to a Friday filing to the Taiwan stock exchange.The company's shares were down 10% in Monday's trade.The drug is used in the treatment of adults with essential thrombocythemia and with polycythemia vera, or PV.Following the approval, PharmaEssentia USA Corporation will start the sales and marketing activities of BESREMi  for essential thrombocythemia in the US.The US FDA approved BESREMi  for the treatment of all adults with PV in November 2021.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663202029","title":"Promisia clears conditions for Chatswood Retirement Village acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2663202029","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663202029?lang=en_us&edition=fundamental","pubTime":"2026-08-31 11:17","pubTimestamp":1788146276,"startTime":"0","endTime":"0","summary":"Promisia Healthcare Limited ( ($NZ:PHL) ) has provided an announcement. Promisia Healthcare has confirmed that all material conditions for its acqu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/promisia-clears-conditions-for-chatswood-retirement-village-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/promisia-clears-conditions-for-chatswood-retirement-village-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XBI","BK4581","BK4588","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663264490","title":"Regis Healthcare Director Boosts Stake with On-Market Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2663264490","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663264490?lang=en_us&edition=fundamental","pubTime":"2026-08-31 10:17","pubTimestamp":1788142657,"startTime":"0","endTime":"0","summary":"Regis Healthcare Ltd. ( ($AU:REG) ) has shared an update. Regis Healthcare has disclosed a change in director Andrew John Kinkade’s interests, with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regis-healthcare-director-boosts-stake-with-on-market-share-purchase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regis-healthcare-director-boosts-stake-with-on-market-share-purchase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","LU0128526141.USD","BK4588","XBI","BK4137","BK4581","LABU","XLV","BK4585","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663602657","title":"Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663602657","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663602657?lang=en_us&edition=fundamental","pubTime":"2026-08-31 09:50","pubTimestamp":1788141015,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS). Bris...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","LU0225284248.USD","LU1868837300.USD","LU1983299246.USD","BK4588","LU1571399168.USD","BK4585","LABU","LU1323610961.USD","LU1585245621.USD","LU1074936037.SGD","LU1261432733.SGD","FTXH","IE00BJT1NW94.SGD","LU1093756168.USD","BK4007","LU2242652126.USD","BK4139","LU0061475181.USD","LU0306806265.USD","LU0237698245.USD","LU1670710661.SGD","LU1718418525.SGD","LU0267386448.USD","XBI","LU2125154778.USD","LU2133065610.SGD","LU1989771016.USD","IE0002141913.USD","LU0029874061.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU1868837136.USD","LU2125154935.USD","HCSG","LU1868836757.USD","LU0114720955.EUR","XLV","LU1032466523.USD","IE00BSNM7G36.USD","LU1670710588.SGD","IHE","LU1868836914.USD","BK4137","LU1883839398.USD","LU0985481810.HKD","IONS","IE00BJJMRZ35.SGD","LU0128526141.USD","BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663258760","title":"Fisher & Paykel Healthcare Issues New Shares for Employee Incentive Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2663258760","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663258760?lang=en_us&edition=fundamental","pubTime":"2026-08-31 09:17","pubTimestamp":1788139034,"startTime":"0","endTime":"0","summary":"Fisher & Paykel Healthcare Corporation Limited ( ($NZ:FPH) ) has shared an announcement. Fisher & Paykel Healthcare has issued 940,000 new ordinary...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fisher-paykel-healthcare-issues-new-shares-for-employee-incentive-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fisher-paykel-healthcare-issues-new-shares-for-employee-incentive-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK8004","BK4581","XLV","FPH.NZ","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":1,"totalSize":399,"code":"91000000","status":"200"}]}}